The order issued by the US Court of Appeals for the Federal Circuit, which has nationwide jurisdiction in various subject areas that include patents, requires Teva to submit a response to the court.
The injunction remains in effect until a decision by the court. Teva launched its generic version “at risk” since patent litigation is still ongoing, and risks potentially significant damages if Novartis prevails. A trial date has not been set.